Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
On January 7, 2011, the Administrators of the US Retirement Savings Plan notified the registrant of an increase in the notional allocation of Ordinary share ADRs. This adjustment followed a re-valuation of the cash element of the notional investment held within the plan. The transaction price was $38.77 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 7, 2011 (Notification date: January 10, 2011).
- Transaction Price: $38.77 per ADR.
- Involved Parties: Mr. W C Louv (8 ADRs), Dr. M M Slaoui (18 ADRs), and Dr. D Pulman (13 ADRs).
- Context: The transaction relates to a re-valuation of the cash element within the US Retirement Savings Plan, not a direct market purchase by the individuals.